Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Prostate Cancer

Clinical Trial at: Compass Oncology - Vancouver

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

  • Details

ClinicalTrials.gov ID: NCT05288166
Diagnosis Type: Prostate Cancer
USOR Number: 21538

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Tigard

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

  • Details

ClinicalTrials.gov ID: NCT05288166
Diagnosis Type: Prostate Cancer
USOR Number: 21538

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Portland

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

  • Details

ClinicalTrials.gov ID: NCT05288166
Diagnosis Type: Prostate Cancer
USOR Number: 21538

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Portland

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

  • Details

ClinicalTrials.gov ID: NCT05288166
Diagnosis Type: Prostate Cancer
USOR Number: 21538

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Portland

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

  • Details

ClinicalTrials.gov ID: NCT05348577
Diagnosis Type: Prostate Cancer
USOR Number: 21493

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Portland

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

  • Details

ClinicalTrials.gov ID: NCT05348577
Diagnosis Type: Prostate Cancer
USOR Number: 21493

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Tigard

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

  • Details

ClinicalTrials.gov ID: NCT05348577
Diagnosis Type: Prostate Cancer
USOR Number: 21493

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

  • Details

ClinicalTrials.gov ID: NCT05348577
Diagnosis Type: Prostate Cancer
USOR Number: 21493

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

  • Details

ClinicalTrials.gov ID: NCT04493853
Diagnosis Type: Prostate Cancer
USOR Number: 20138

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Compass Oncology - Tigard

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

  • Details

ClinicalTrials.gov ID: NCT04493853
Diagnosis Type: Prostate Cancer
USOR Number: 20138

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page
1 2

Find a Location

With more than 1,400 physicians and over 500 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.